Ikena Oncology Entered into a Clinical Trial Collaboration Agreement with AstraZeneca for IK-930 to Treat EGFR-Mutated Non-Small Cell Lung Cancer
Shots:
- The companies collaborated to evaluate Tagrisso + Ikena’s IK-930 for EGFRm NSCLC. The companies also provided an R&D update on IK-930, a TEAD inhibitor addressing the Hippo signaling pathway
- IK-930 is currently being evaluated as a monothx. in a first-in-human P-I trial for advanced solid tumors incl. NF2-deficient malignant mesothelioma & initial clinical results are expected in 2023
- In the preclinical studies, IK-930 + osimertinib resulted in increased induction of apoptosis & improved anti-tumor activity in multiple EGFRm tumor models. The results will be presented at upcoming conferences on the effectiveness and differentiation of IK-930 in multiple animal models as monothx. and in combination with other targeted therapies
Ref: Globenewswire | Image: AstraZeneca
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
